Overview
Off‑label use refers to the prescription of a medication in a manner not specified in the official approval granted by a regulatory authority. This can include using a drug to treat a condition for which it was not approved, giving it to an age group not studied in the approval process, using a different dose or schedule, or employing an alternate route of administration. The practice is widespread in many areas of medicine where formal studies are incomplete or evolving.
How it arises and regulatory context
Regulatory approvals are based on evidence from clinical trials submitted by manufacturers. Once a drug is approved, licensed prescribers in most jurisdictions may legally prescribe it off‑label if they judge it appropriate for a patient. However, manufacturers are typically restricted from promoting off‑label uses. For basic information about a specific product, see the label of the prescription drug and public regulatory summaries such as those produced by national agencies. Clinical trials and post‑marketing studies remain central to expanding safe, evidence‑based uses (clinical trial registries).
Clinical practice and common examples
Off‑label prescribing is common in specialties that treat conditions with limited approved therapies, such as pediatrics, oncology, and rare diseases. Examples include using an approved anticonvulsant for mood stabilization, repurposing an antihypertensive for migraine prevention, or trying a medication approved in adults for a child when no dedicated pediatric approval exists. Clinicians base such decisions on scientific literature, clinical experience, guidelines, and individual patient factors.
Evidence, safety and ethical considerations
Because off‑label use lies outside the formal approval, the strength of evidence can vary widely. Important considerations include:
- Quality of supporting studies or guidelines
- Known safety profile and potential for unexpected harms
- Alternative approved treatments
- Informed consent and clear communication with the patient or caregiver
Clinicians should document rationale and monitor outcomes. For drug‑specific information providers may consult the product monograph or specialist reviews, including resources provided for the regulatory review.
Practical and policy implications
Insurance coverage for off‑label uses varies and may depend on recognized compendia or guideline endorsement. Research into off‑label applications can lead to formal new indications if sufficient evidence accumulates, resulting in label changes and broader access. At the same time, inappropriate off‑label promotion or use without adequate evidence has prompted regulatory and professional guidance to ensure patient safety.
Notable distinctions
Off‑label prescribing is distinct from experimental use in clinical trials: the former is a routine medical decision documented in clinical care, while the latter is performed under research protocols with ethics oversight. It is also different from compounding or alternative therapies. Understanding these boundaries helps clinicians, patients, and policymakers balance innovation with safety.